Skip to main content
CTOS 2024 Main banner
Final Program


Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Michael J. Nathenson, MD (he/him/his)

Senior Medical Director
Adaptimmune
Cambridge, Massachusetts, United States

Michael graduated summa cum laude with a B.S. in biology from the Brandeis University in 2005. He completed medical school, graduating with honors from Tufts University School of Medicine in 2009. He went on to complete a residency in internal medicine at the University of Pittsburgh Medical Center, and then a hematology/oncology fellowship at the University of Maryland Medical Center. Michael is boarded in internal medicine, oncology, and hematology. He completed an additional one-year sarcoma medical oncology fellowship at the MD Anderson Cancer Center in Houston Texas focusing on soft tissue and bone sarcomas.
After completion of training, Michael joined the sarcoma medical oncology group at the Dana-Farber Cancer Institute in July of 2016 out of a deep commitment to advancing sarcoma care, treatment, and research. At the Dana-Farber Cancer Institute, Michael treated over 1000 sarcomas patients, and helped to develop and lead sarcoma and immunotherapy clinical trials. Throughout his training, he gained clinical experience at some of the leading cancer treatment centers in the nation, the University of Pittsburgh, the University of Maryland, MD Anderson in Houston Texas, and the Dana-Farber Cancer Institute in Boston Massachusetts. He was site lead investigator for the phase III nirogacestat trial in desmoid fibromatosis. He led multiple retrospective reviews for osteosarcoma, rhabdomyosarcoma, CIC-DUX4 sarcomas, and uterine adenosarcoma. He was responsible for the design, implementation, and conduct of the phase II eribulin + pembrolizumab trial in soft tissue sarcomas.
From February 2021 to April 2023 Michael joined GSK first as a medical director, and then as a senior medical director and was responsible for the Lete-cel pilot trials in synovial sarcoma and myxoid liposarcomas, and the lete-cel IGNYTE trial.
In April 2023 Michael joined Adaptimmune and is currently supporting development of lete-cel.

Disclosure information not submitted.

Presentation(s):

Email Michael